Zion Market Research has published a new report titled “Radiopharmaceutical Market by Type (Diagnostic Radiopharmaceuticals and Therapeutic radiopharmaceuticals), for Cardiology, Neurology, Oncology and Other Applications- Global Industry Perspective, Comprehensive Analysis, Size, Share, Growth, Segment, Trends and Forecast, 2015 – 2021”. According to the report, global radiopharmaceutical market was valued at around USD 4.32 billion in 2015, is expected to reach approximately USD 7.13 billion in 2021, growing at a CAGR of more than 8.8% between 2016 and 2021.
Radiopharmaceutical is a medication used in nuclear medicine that has the radioactive part and pharmaceutical part. Nuclear medication is given to a patient in a small amount; this makes patient body radioactive for the short time span. A special nuclear medicine camera detects the radiation emitted from the body and takes images on inner body organs to check its function. Most of the radiopharmaceuticals used in diagnostic nuclear medicine procedures emit gamma radiation. The most commonly used gamma emitting radionuclide in nuclear medicine is 99mTechnetium, which is labeled to different types of pharmaceuticals to formulate diagnostic imaging agent’s i.e radiopharmaceuticals.
Request Free Sample copy of Research Report @ https://www.zionmarketresearch.com/sample/radiopharmaceutical-market
The global radiopharmaceuticals market is growing at a significant pace owing to increasing preference of disease targeted cancer therapy, expanding the application of molecular imaging and growing patient awareness for accurate diagnosis of disease. However, factors such as shorter half-life of radiopharmaceuticals and stringent regulatory guidelines can hamper the radiopharmaceutical market worldwide.
Radiopharmaceutical market is segmented on the basis of type and applications. Depending on type global radiopharmaceutical market is divided into diagnostic radiopharmaceuticals and therapeutic radiopharmaceuticals. The diagnostic radiopharmaceuticals market dominated the overall radiopharmaceutical market in terms of market share owing to the high usage rate of molecular imaging techniques in the field of medical diagnosis. The SPECT modality segment dominated the radiopharmaceuticals market in 2015. The PET modality segment is expected to grow at a comparatively higher rate in forecast period due to the better quality of the image and higher precision in diagnosis. Additionally, PET segment growth is attributed to growing R&D activities especially in emerging economies and widening the scope of radiopharmaceutical applications such as oncology, thyroid, and bone pain palliation.
Browse the full “Radiopharmaceutical Market by Type (Diagnostic Radiopharmaceuticals and Therapeutic radiopharmaceuticals), for Cardiology, Neurology, Oncology and Other Applications- Global Industry Perspective, Comprehensive Analysis, Size, Share, Growth, Segment, Trends and Forecast, 2015 – 2021” report at https://www.zionmarketresearch.com/report/radiopharmaceutical-market
Oncology, cardiology, neurology, and other are the key application of the radiopharmaceutical market. The oncology segment contributed more than half of the market share in the overall radiopharmaceuticals market in 2015. This segment is expected to continue the same trend owing to the perpetual rise in the number of cancer cases.
North America held the largest market share in the global radiopharmaceuticals market in 2015. The Asia-Pacific radiopharmaceuticals market, on the other hand, will grow at the fastest rate during the forecast period owing to a rise in the demand for PET and SPECT devices. This growth was induced by rising patient awareness levels pertaining to cardiovascular diseases and oncology. The leading Asia-Pacific countries, such as China, Japan and India would exhibit a steady growth rate during the estimated period.
Inquire more about this report before purchase @ https://www.zionmarketresearch.com/inquiry/radiopharmaceutical-market
Cardinal Health, Inc., GE Healthcare, Bracco Imaging S.p.A, Eczacibasi-Monrol Nuclear Products, Nordion, Inc., Advanced Accelerator Applications S.A., Bayer Healthcare, Lantheus Medical Imaging, Inc., IBA Molecular Imaging, Mallinckrodt plc, Jubilant Pharma, and Siemens Healthcare are some of the leading profiles in the radiopharmaceutical market.
Zion Market Research is an obligated company. We create futuristic, cutting edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.
Zion Market Research
4283, Express Lane,
Sarasota, Florida 34249, United States
Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651